Irras AB is Sweden- based medical device company primarily engaged in develops and commercializes solutions that are designed to transform neurocritical care. Company focus on neurosurgical procedures, where excess cerebrospinal fluid (CSF) or toxic blood byproducts often need to be emergently drained and intracranial pressure (ICP) needs to be closely regulated.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Market Cap	182M 18.51M 16.12M 15.26M 13.86M 25.9M 1.77B 26.03M 70.28M 901M 69.54M 67.99M 2.88B	P/E 2023	-0.73x	P/E 2024	-1.89x
Enterprise Value	396M 40.28M 35.09M 33.21M 30.17M 56.37M 3.86B 56.64M 153M 1.96B 151M 148M 6.28B	EV / Sales 2023	5.26x	EV / Sales 2024	6.82x
Free-Float	3.55%	Yield 2023 *	-	Yield 2024	-

28/06/25	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/06/24	IRRAS AB Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03/11/23	Irras has today its last day of trading on Nasdaq Stockholm before delisting	FW
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index	CI
24/10/23	IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index	CI
23/10/23	Irras Obtains Nasdaq Approval for Delisting in Stockholm	MT
20/10/23	Irras delisted from Nasdaq Stockholm with last trading day on November 3	FW
20/10/23	Sweden's Irras Files for Delisting as Privatization Nears Completion	MT
20/10/23	IR Holding Bidco calls for compulsory acquisition in Irras - applies for delisting	FW
16/10/23	Irras Obtains Extension for SEK20 Million Loan	MT
16/10/23	Irras extends SEK 20 million short-term loan	FW
02/10/23	Bidder controls 87.9 percent of the shares in Irras after completion of takeover bid	FW
19/09/23	Set-off issue only realistic option to avoid insolvency situation - Irra Board	FW

30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv(R)	FW
30/06/23	Bid for Irras below historical median premium - but also high risk of more fundraising - Afv	FW
22/05/23	Irra's Q1 sales below expectations - Redeye predicts new share issue and halves fair value	FW
22/05/23	Redeye lowers motivated value for Irras to SEK 0.15 (0.30)	FW
20/02/23	Redeye reiterates motivated value for Irras, but predicts capital raising this year	FW

20/10/23	IRRAS's application for delisting has been approved and the Board of Directors has resolved not to publish the interim report for the third quarter of 2023	AQ
20/10/23	NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF IRRAS AB	AQ
20/10/23	IR Holding Bidco Inc. requests compulsory buy-out and IRRAS applies for delisting	AQ
16/10/23	IRRAS publishes prospectus	AQ
15/10/23	IRRAS has extended maturity date for its SEK 20 million short-term loan	AQ

Manager	Title	Age	Since
Will Martin CEO	Chief Executive Officer	51	01/07/2021
Griffen Stapp DFI	Director of Finance/CFO	40	17/06/2021
Sten Gustafsson IRC	Investor Relations Contact	-	09/03/2021

IRRAS AB (publ) Stock London S.E.

Stocks

0GDW

SE0008321202

Medical Equipment, Supplies & Distribution

Valuation: IRRAS AB (publ)

Latest news: IRRAS AB (publ)

Analysts' recommendations: IRRAS AB (publ)

Press Releases: IRRAS AB (publ)

Quotes and Performance

Managers and Directors: IRRAS AB (publ)

Medical Devices & Implants

Financials

Company Profile

Director	Title	Age	Since
Kleanthis Xanthopoulos BRD	Director/Board Member	68	01/06/2015
Marios Fotiadis CHM	Chairman	53	18/08/2020
Inger Gunnel Anita Tollstadius BRD	Director/Board Member	71	01/09/2017

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IRRAS AB (PUBL)	-3.63%	-70.75%	-	-	16.9M
STRYKER CORPORATION	-1.63%	+3.75%	-25.67%	-4.32%	107B
SMITH & NEPHEW PLC	-0.24%	+2.43%	-24.43%	-1.48%	11.63B
GLAUKOS CORPORATION	-1.25%	-5.26%	+96.61%	+114.88%	9.52B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-0.05%	-0.06%	-53.24%	-71.50%	3.99B
DOUBLE MEDICAL TECHNOLOGY INC.	+0.03%	-2.86%	-29.22%	+21.70%	2.33B
INSPIRE MEDICAL SYSTEMS, INC.	-0.01%	+6.78%	-9.08%	-65.51%	2.1B
INSIGHT LIFETECH CO., LTD.	+0.95%	+1.34%	-	-	1.84B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-0.23%	-0.91%	-22.21%	-30.30%	1.52B
Average	-0.67%	+1.08%	-9.61%	-5.22%	17.55B
Weighted average by Cap.	-1.34%	+2.74%	-17.73%	+1.40%

	2023	2024
Net sales	42.88M 4.37M 3.8M 3.6M 3.27M 6.11M 418M 6.14M 16.58M 213M 16.41M 16.04M 680M	57.98M 5.91M 5.14M 4.87M 4.42M 8.26M 566M 8.3M 22.42M 287M 22.18M 21.69M 920M
Net income	-209M -21.27M -18.53M -17.54M -15.93M -29.77M -2.04B -29.91M -80.77M -1.04B -79.92M -78.14M -3.31B	-95.98M -9.78M -8.51M -8.06M -7.32M -13.68M -936M -13.75M -37.11M -476M -36.72M -35.91M -1.52B
Net Debt	43.85M 4.47M 3.89M 3.68M 3.34M 6.25M 428M 6.28M 16.95M 217M 16.78M 16.4M 696M	214M 21.77M 18.96M 17.95M 16.31M 30.47M 2.09B 30.62M 82.67M 1.06B 81.79M 79.97M 3.39B